Figure 2.

No synergistic antitumor activity of full-dose oxaliplatin and anti-TIGIT mAb. (A), Experimental scheme for CT26 colon cancer model used in (B, C). Mice were given injection of Rat IgG, anti-TIGIT mAb (10 mg/kg), OX (6 mg/kg), or anti-TIGIT mAb combined with OX intraperitoneally (i.p.) at various times after injection of 5×10⁴ CT26 cells subcutaneously (s.c.) on day 0. (B), Tumor size measurement at each time point. (n=6-8 mice per group). (C), Overall survival of CT26-bearing mice with various treatments. (D), Experimental scheme for CT26 colon cancer model used in (E–H). Mice were given injection of Rat IgG, anti-TIGIT mAb, various-dose OX or anti-TIGIT mAb combined with various-dose OX intraperitoneally (i.p.) at various times after injection of 5×10⁴ CT26 cells subcutaneously (s.c.) on day 0. (E), Tumor size measurement at each time point. (n=6-8 mice per group). (F), Overall survival of CT26-bearing mice with various treatments. (G), Representative photograph and (H) weight of tumor (n = 5 per group) on day 21 after challenge. Scale bar represents 2 cm. Data were representative of at least two independent experiments. Error bars represent means ± SEM. Statistical significance was determined using two-way ANNOVA (B, E), Mantel–Cox test (C, F) or one-way ANOVA followed by Tukey’s multiple-comparisons (H). ns, p > 0.05; *p < 0.05 and **p < 0.01.